Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (251-260 of 324) with videos related to

Pageof 33
Sort By:
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
Cell Reports|November 25, 2020
Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization EscapeCathrine Scheepers, Valerie Bekker, Colin Anthony, et al.
The Lancet. Infectious Diseases|December 4, 2018
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trialSinead Delany-Moretlwe, Carl Lombard, Deborah Baron, et al.
Cell Reports|April 9, 2020
Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex RecognitionJason Gorman, Gwo-Yu Chuang, Yen-Ting Lai, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2025
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibodySharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, et al.
Journal of Virology|May 11, 2012
The development of CD4 binding site antibodies during HIV-1 infectionRebecca M Lynch, Lillian Tran, Mark K Louder, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Nature Medicine|October 23, 2012
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escapePenny L Moore, Elin S Gray, C Kurt Wibmer, et al.
Journal of Virology|September 26, 2008
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and CJames M Binley, Elizabeth A Lybarger, Emma T Crooks, et al.
Pageof 33

Showing results (251-260 of 324) with videos related to

Sort By:
Pageof 33
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
Cell Reports|November 25, 2020
Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization EscapeCathrine Scheepers, Valerie Bekker, Colin Anthony, et al.
The Lancet. Infectious Diseases|December 4, 2018
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trialSinead Delany-Moretlwe, Carl Lombard, Deborah Baron, et al.
Cell Reports|April 9, 2020
Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex RecognitionJason Gorman, Gwo-Yu Chuang, Yen-Ting Lai, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2025
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibodySharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, et al.
Journal of Virology|May 11, 2012
The development of CD4 binding site antibodies during HIV-1 infectionRebecca M Lynch, Lillian Tran, Mark K Louder, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Nature Medicine|October 23, 2012
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escapePenny L Moore, Elin S Gray, C Kurt Wibmer, et al.
Journal of Virology|September 26, 2008
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and CJames M Binley, Elizabeth A Lybarger, Emma T Crooks, et al.
Pageof 33